AGP Executive Report
Last update: 3 hours agoDrug Safety: Italy-based Newron says the FDA is maintaining a clinical hold on its late-stage schizophrenia programme after deaths were reported in drug studies, delaying development. Cancer Treatment: A Dutch court has blocked Merck’s under-the-skin Keytruda from sale in Italy and seven other European markets, ruling that it infringes a rival company’s patent. Healthy Ageing: Researchers are investigating a Sardinian village where women appear to live exceptionally long lives; the community is being explored as a possible longevity hotspot, not yet confirmed as a new “blue zone.” Obesity Care: Rising obesity rates in Italy have renewed debate over whether the national health system should cover weight-loss medicines such as Ozempic.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.
Perspectify News
